Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis → A New Generation of Billionaires Is About to Be Created (From Banyan Hill Publishing) (Ad) Free IMCR Stock Alerts $42.55 -0.14 (-0.33%) (As of 12:18 PM ET) Add Compare Share Share Today's Range$42.45▼$43.1250-Day Range$42.69▼$65.0052-Week Range$41.01▼$76.98Volume48,021 shsAverage Volume608,517 shsMarket Capitalization$2.13 billionP/E RatioN/ADividend YieldN/APrice Target$81.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunocore alerts: Email Address Immunocore MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside92.2% Upside$81.85 Price TargetShort InterestBearish10.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.88) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector594th out of 905 stocksBiological Products, Except Diagnostic Industry97th out of 150 stocks 4.4 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunocore has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.66% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Immunocore has recently increased by 13.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 1.9 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Immunocore this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Immunocore is held by insiders.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.88) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -34.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -34.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingWhy June 30 Will Be the Tipping Point for AIAI is already replacing workers in warehouses. It’s spreading like lightning in the software, legal and engineering industries… It’s now estimated at least 300 million jobs worldwide are in AI’s crosshairs.Click here for details. About Immunocore Stock (NASDAQ:IMCR)Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesJune 6 at 4:22 AM | americanbankingnews.comImmunocore (NASDAQ:IMCR) Stock Rating Reaffirmed by HC WainwrightJune 4 at 3:52 AM | americanbankingnews.comImmunocore's (IMCR) Buy Rating Reaffirmed at Needham & Company LLCJune 1, 2024 | globenewswire.comImmunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseMay 31, 2024 | globenewswire.comImmunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024May 31, 2024 | americanbankingnews.comImmunocore's (IMCR) Buy Rating Reaffirmed at HC WainwrightMay 30, 2024 | globenewswire.comImmunocore to present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comImmunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaMay 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)May 24, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)May 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.May 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic DevelopmentsMay 18, 2024 | investing.comImmunocore Holdings PLC (IMCR)May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)May 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter ReportMay 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunocore Holdings on Strong KIMMTRAK Sales and Promising Pipeline GrowthMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)May 9, 2024 | markets.businessinsider.comImmunocore Holdings Outperforms with Kimmtrak Sales Surpassing Estimates; Maintains Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Immunocore Holdings on Strong Financials and Expanding Innovative PipelineMay 8, 2024 | finance.yahoo.comImmunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue ForecastsMay 8, 2024 | investorplace.comIMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deImmunocore Holdings plc: Immunocore reports first quarter financial results and provides a business updateMay 8, 2024 | globenewswire.comImmunocore reports first quarter financial results and provides a business updateApril 30, 2024 | msn.comLeerink Partners Initiates Coverage of Immunocore Holdings plc - Depositary Receipt () (IMCR) with Outperform RecommendationApril 26, 2024 | finanznachrichten.deImmunocore Holdings plc: Immunocore announces upcoming presentation and posters at ASCO 2024See More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/07/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees497Year FoundedN/APrice Target and Rating Average Stock Price Target$81.85 High Stock Price Target$100.00 Low Stock Price Target$67.00 Potential Upside/Downside+92.4%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-22.60% Pretax Margin-24.91% Return on Equity-16.54% Return on Assets-8.75% Debt Debt-to-Equity Ratio1.22 Current Ratio5.96 Quick Ratio5.94 Sales & Book Value Annual Sales$249.43 million Price / Sales8.53 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book5.73Miscellaneous Outstanding Shares50,010,000Free Float45,461,000Market Cap$2.13 billion OptionableOptionable Beta0.83 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 63)CEO & Executive Director Comp: $1.38MMr. Brian R. Di Donato M.B.A. (Age 57)CFO & Head of Strategy Comp: $654.46kMs. Tina St. Leger (Age 56)Chief Human Resources Officer Comp: $509.12kDr. David Berman M.D. (Age 53)Ph.D., Head of Research & Development Comp: $796.62kMr. John Trainer M.B.A. (Age 50)SVP & Chief Operating Officer Mr. John Goll IIISVP, Finance & Chief Accounting OfficerMs. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchMr. Sean D. Buckley (Age 41)VP & Chief Information Officer Clayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGeneral Counsel & Company SecretaryMore ExecutivesKey CompetitorsRepligenNASDAQ:RGENVaxcyteNASDAQ:PCVXExelixisNASDAQ:EXELRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 6,510 shares on 5/17/2024Ownership: 0.013%Janus Henderson Group PLCBought 80,748 shares on 5/16/2024Ownership: 0.516%Jane Street Group LLCBought 28,700 shares on 5/16/2024Ownership: 0.000%Price T Rowe Associates Inc. MDSold 506,990 shares on 5/15/2024Ownership: 4.893%Bellevue Group AGSold 3,800 shares on 5/15/2024Ownership: 1.952%View All Insider TransactionsView All Institutional Transactions IMCR Stock Analysis - Frequently Asked Questions Should I buy or sell Immunocore stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks. What is Immunocore's stock price target for 2024? 15 Wall Street analysts have issued 1 year price objectives for Immunocore's stock. Their IMCR share price targets range from $67.00 to $100.00. On average, they expect the company's share price to reach $81.85 in the next twelve months. This suggests a possible upside of 92.2% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts. How have IMCR shares performed in 2024? Immunocore's stock was trading at $68.32 at the beginning of the year. Since then, IMCR stock has decreased by 37.7% and is now trading at $42.59. View the best growth stocks for 2024 here. When is Immunocore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our IMCR earnings forecast. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.12. The business earned $70.30 million during the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative trailing twelve-month return on equity of 16.54% and a negative net margin of 22.60%. The company's quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. What ETFs hold Immunocore's stock? ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA) and Tema Oncology ETF (CANC).BlackRock Future Health ETF (BMED). When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.89%), Baker BROS. Advisors LP (3.04%), Bellevue Group AG (1.95%), Principal Financial Group Inc. (1.04%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.69%) and Janus Henderson Group PLC (0.52%). View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMCR) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by Au...The Freeport Society | SponsoredBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
